The short-term IOP-lowering effect of brimonidine 0.2% and dorzolomide 2% combination in primary open-angle glaucoma

Abstract

Purpose: To evaluate the ocular hypotensive effect of dorzolamide 2% in primary open-angle glaucoma (POAG) patients with intraocular pressure (IOP) of at least 22mmHg despite ongoing twice daily treatment with brimonidine 0.2%. Patients and Methods: Nineteen eyes of 19 patients with POAG and IOP ≥ 22 mmHg, on twice daily brimonidine therapy, were included in the study. Intraocular pressure and adverse effects were recorded on days 2, Results: Mean pretreatment IOP was 27.6 ± 2.2 mmHg. This decreased to 24.2 ± 2.2 mmHg after a mean duration of 23.8 ± 12.1 days. After dorzolamide was added to the treatment, mean IOP was 20.8 ± 2.3 mmHg on day 2, 19.3 ± 2.2 mmHg on day 7, 18.0 ± 2.5 mmHg on day 14 and 17.2 ± 2.3 mmHg on day 30. The differences between pre- and post-treatment IOP values were statistically significant (p <0.0001, anova test). Conclusion: Dorzolamide administered three times daily has significant additive ocular hypotensive effect in POAG patients whose IOP is elevated despite ongoing treatment with brimonidine.